It is a link to move within the page

Press Release


March 31, 2006

Torii Pharmaceutical Co., Ltd.
Teikoku Seiyaku Co., Ltd.
Conclusion of Co-marketing Agreement for Dovonex® Ointment for
the Treatment of Psoriasis Vulgaris
Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo; hereinafter called "Torii") and Teikoku Seiyaku Co., Ltd. (Head Office: Kagawa Pref., President: Shosaku Murayama; hereinafter called "Teikoku Seiyaku") announced today that the companies signed a co-marketingagreement for "Dovonex® Ointment" (generic name: calcipotriol ointment) for the treatment of psoriasis vulgaris.

"Dovonex® Ointment" is a skin cream based on an active form of vitamin D3 developed by Teikoku Seiyaku in Japan under license from LEO Pharmaceutical Products Ltd. A/S of Denmark. Teikoku Seiyaku obtained approval to import the drug on January 18, 2000. It is now jointly marketed and distributed by Astellas Pharma Inc. and Teikoku Medix Co., Ltd., a subsidiary of Teikoku Seiyaku. Torii will join the sales and information distribution activities in Japan under the present agreement (from October 2006).

[Reference: Outline of "Dovonex® Ointment"]
Product name: Dovonex® Ointment
Concentration of active ingredient: 50 µg of calcipotriol/g
Indication: Psoriasis vulgaris
Dosage and administration: Usually, an appropriate amount of the drug is applied to the affected area twice daily.
Packaging: 10 and 30 g
Launch date: June 2000
NHI (reimbursement) price: 0.005% 1g: 141.90 Yen (after NHI price revision in April 2006)
Manufacturer/distributor: Teikoku Seiyaku Co., Ltd.

It is the end of the page